Investor List:

Top BioTech Series B Investors in Boston / New England (183)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top BioTech investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Bill Helman, Partner at Greylock
Bill Helman
Greylock·Partner
Sweet spot: $25.0M
Range: $500K - $200.0M
Investors in Boston (MA)
Photo of Jason Ruth, Principal at 5am Ventures
Jason Ruth
5am Ventures·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in United States, Investors in Boston / New England, Investors in Boston (MA), Investors in Cambridge (MA)
Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series B), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Boston / New England (Other Lists)
Photo of Andrew Hedin, Partner at Bessemer Venture Partners
Andrew Hedin
Sweet spot: $25.0M
Range: $1M - $250.0M
Investors in Redwood City (CA), Investors in Boston (MA)
Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Digital Health (Seed), Investors in Consumer Internet (Series B), Investors in Consumer Health (Series B), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Consumer Health (Seed), Investors in Consumer Health (Series A), Investors in Consumer Internet (Series A), Investors in Digital Health (Series B), Investors in Consumer Internet (Seed), Investors in Consumer Health (Series B), Investors in Consumer Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Health IT (Series B), Investors in Consumer Health (Series A), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Seed), Investors in Consumer Health (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Boston / New England (Other Lists), Investors in Consumer Internet (Series B), Investors in Health IT (Seed), Investors in Consumer Internet (Series B), Investors in Consumer Internet (Series A), Investors in Consumer Internet (Seed), Investors in Consumer Internet (Series A), Investors in Consumer Internet (Seed), Investors in San Francisco Bay Area (Other Lists)
Photo of Michael McArdle, Managing Director at Bain Capital
Michael McArdle
Bain Capital·Managing Director
Sweet spot: $25.0M
Range: $1M - $100.0M
Investors in Boston (MA)
Photo of Matthew Evans, Managing Director at Bain Capital
Matthew Evans
Bain Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Enterprise Applications (Series B), Investors in E-commerce (Series B), Investors in Enterprise Applications (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Enterprise Applications (Seed), Investors in BioTech (Series B), Investors in Health IT (Series A), Investors in E-commerce (Series A), Investors in Health & Hospital Services (Series A), Investors in E-commerce (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Enterprise (Series B), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Insurance (Series B), Investors in Insurance (Series A), Investors in Real Estate/PropTech (Series B), Investors in FinTech (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise (Series A), Investors in Real Estate/PropTech (Series A), Investors in Web3/Crypto (Series A), Investors in Enterprise Applications (Series B), Investors in Enterprise (Seed), Investors in Insurance (Series B), Investors in Enterprise Applications (Seed), Investors in FinTech (Series B), Investors in Real Estate/PropTech (Seed), Investors in Web3/Crypto (Series B), Investors in Insurance (Seed), Investors in Insurance (Seed), Investors in FinTech (Series A), Investors in E-commerce (Series B), Investors in Web3/Crypto (Seed), Investors in BioTech (Series B), Investors in Real Estate/PropTech (Series B), Investors in Insurance (Series A), Investors in Real Estate/PropTech (Series A), Investors in Real Estate/PropTech (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Web3/Crypto (Series B), Investors in BioTech (Series A), Investors in Web3/Crypto (Series A), Investors in BioTech (Seed), Investors in Web3/Crypto (Seed), Investors in Health & Hospital Services (Series A), Investors in E-commerce (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Seed), Investors in E-commerce (Seed), Investors in FinTech (Series B), Investors in Health IT (Seed), Investors in Enterprise (Series B), Investors in FinTech (Series A), Investors in FinTech (Seed), Investors in Enterprise (Series A), Investors in Enterprise (Seed), Investors in Boston / New England (Other Lists)
Photo of Michael A. Ewald, Managing Director at Bain Capital
Michael A. Ewald
Bain Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in E-commerce (Series B), Investors in Enterprise Applications (Series B), Investors in Enterprise Applications (Series A), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series B), Investors in E-commerce (Series A), Investors in Health IT (Series B), Investors in Enterprise Applications (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in E-commerce (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in FinTech (Series B), Investors in Health IT (Seed), Investors in Enterprise (Series B), Investors in Insurance (Series B), Investors in FinTech (Seed), Investors in Insurance (Series A), Investors in Real Estate/PropTech (Series B), Investors in Web3/Crypto (Series A), Investors in Enterprise (Series A), Investors in Real Estate/PropTech (Series A), Investors in Enterprise Applications (Series B), Investors in Enterprise (Seed), Investors in Insurance (Series B), Investors in Real Estate/PropTech (Seed), Investors in Web3/Crypto (Series B), Investors in Enterprise Applications (Seed), Investors in Enterprise Applications (Series A), Investors in Insurance (Seed), Investors in FinTech (Series A), Investors in Insurance (Series A), Investors in Web3/Crypto (Seed), Investors in Real Estate/PropTech (Series B), Investors in BioTech (Series B), Investors in E-commerce (Series B), Investors in Real Estate/PropTech (Series A), Investors in Real Estate/PropTech (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Insurance (Seed), Investors in Web3/Crypto (Series B), Investors in BioTech (Series A), Investors in Web3/Crypto (Series A), Investors in BioTech (Seed), Investors in Web3/Crypto (Seed), Investors in E-commerce (Series A), Investors in Health & Hospital Services (Series A), Investors in E-commerce (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in FinTech (Series B), Investors in Enterprise (Series B), Investors in FinTech (Series A), Investors in FinTech (Seed), Investors in Enterprise (Series A), Investors in Enterprise (Seed), Investors in Boston / New England (Other Lists)
Photo of Max de Groen, Managing Director at Bain Capital
Max de Groen
Bain Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Enterprise Applications (Seed), Investors in Enterprise Applications (Series B), Investors in Enterprise Applications (Series A), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Web3/Crypto (Series B), Investors in BioTech (Series A), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Series A), Investors in Real Estate/PropTech (Seed), Investors in BioTech (Seed), Investors in Web3/Crypto (Seed), Investors in FinTech (Series B), Investors in Enterprise Applications (Series B), Investors in Enterprise Applications (Series A), Investors in FinTech (Series A), Investors in Real Estate/PropTech (Series B), Investors in Insurance (Series B), Investors in FinTech (Seed), Investors in Insurance (Series B), Investors in Insurance (Series A), Investors in Insurance (Seed), Investors in Real Estate/PropTech (Series B), Investors in Enterprise Applications (Seed), Investors in Web3/Crypto (Series A), Investors in Real Estate/PropTech (Series A), Investors in Insurance (Seed), Investors in BioTech (Series B), Investors in Web3/Crypto (Series B), Investors in Insurance (Series A), Investors in Health & Hospital Services (Series B), Investors in Real Estate/PropTech (Seed), Investors in BioTech (Series A), Investors in Real Estate/PropTech (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Seed), Investors in Web3/Crypto (Series A), Investors in Web3/Crypto (Seed), Investors in Health & Hospital Services (Seed), Investors in FinTech (Series B), Investors in FinTech (Series A), Investors in FinTech (Seed), Investors in Boston / New England (Other Lists)
Photo of David Schenkein, General Partner at GV (Google Ventures)
David Schenkein
GV (Google Ventures)·General Partner
Sweet spot: $25.0M
Range: $250K - $50.0M
Investors in Boston (MA), Investors in Boston / New England